MedTrace Logo

A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]-JNJ-70099731 in Healthy Male Participants

NCT04911543 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2025-04-27

No results posted yet for this study

Summary

The purposes of this study are to measure the whole-body distribution and radiation dosimetry of \[18F\]-JNJ-70099731 (Part A), to measure the uptake, distribution, and clearance (CL) of \[18F\]-JNJ-70099731 by Positron Emission Tomography (PET) and to model tissue specific kinetics of \[18F\]-JNJ-70099731 with the appropriate input function (IF) (Part B), and to measure participant test-retest variability in the distribution of \[18F\]-JNJ-70099731 by comparing PET scans obtained at least 1 week apart (Part C) in the brain of healthy male participants.

Conditions

  • Healthy

Interventions

DRUG

[18F]-JNJ-70099731

\[18F\]JNJ-70099731 injection will be administered intravenously.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-23
Primary Completion
2022-02-01
Completion
2022-02-01

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04911543 on ClinicalTrials.gov